New treatments for clear cell kidney cancer
Official title: Exploring novel therapeutic strategies for combinatory therapy to treat renal clear cell carcinomas
Funded at University of Florida · NIH-11010355 · Data updated 2026-11-12
This study is looking for new ways to treat kidney cancer by understanding how the cancer interacts with the body’s immune system and using special tools to target and break down proteins that help the cancer grow, all with the goal of finding better treatments for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Florida NIH-funded |
| Lab location | 1 site (Gainesville, United States) |
| Project start | January 1, 2023 |
| Project end | December 31, 2027 |
| Funding year | 2025 |
| Award (this year) | $499,609 |
| NIH project number | 5R01CA269661-03 |
| Project ID | NIH-11010355 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with renal clear cell carcinoma who may not have responded well to current therapies.
✕Less likely to help
Patients with other types of kidney cancer or those who have already achieved complete remission may not benefit from this research.
What this research studies
This research focuses on developing innovative therapies for renal clear cell carcinomas, a common type of kidney cancer. The approach involves analyzing the tumor microenvironment and the immune response to identify new treatment strategies, including the use of Proteolysis Targeting Chimeras (PROTACs) to degrade specific proteins that contribute to cancer growth. By utilizing advanced techniques like single-cell RNA sequencing, the research aims to uncover the mechanisms behind the cancer's resistance to existing therapies and improve patient outcomes.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for patients with renal clear cell carcinomas.
How similar studies have gone: Previous research has shown promise in targeting similar pathways in cancer treatment, indicating potential for success with this novel approach.
Where this research is happening
-
University of Florida
Gainesville, United States Active
Researchers
- Principal investigator: Zhang, Weizhou — University of Florida
- Study coordinator: Zhang, Weizhou
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.